GLNS advises Ada Health on USD 90m Series B financing led by Bayer

Ada Health GmbH, a Berlin-based digital health company, has announced its USD 90m Series B financing round. Leaps by Bayer acted as lead investor. In addition, among others Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures participated in the round.

Ada Health has developed a powerful AI-based health assessment and care navigation platform that helps users to understand their symptoms, to identify and differentiate conditions with a high degree of medical accuracy, and to navigate safely to the right care, at the right time. Ada’s consumer app has become the world’s most popular and highest-rated symptom assessment app, with over 23 million assessments completed since its global launch.

Leaps by Bayer is the impact investment unit of life science company Bayer AG, which uses its investments to find solutions to some of the biggest challenges of our time in the areas of health and agriculture.

GLNS advised Ada Health on the financing round with a team consisting of lawyers Dr. Daniel Gubitz and Eva Maier (both Corporate Law/Venture Capital). STOUT with a team led by Mathis Wilke acted as financial adviser. Bayer was represented by a team from SMP around Dr. Stephan Bank. Dr. Maximilian Murawo of Hyazinth in Berlin notarized the transaction.

Download press release